A Randomised Phase II Study of Neoadjuvant TAK-700 and Leuprorelin Acetate Followed by Surgery Versus Surgery Alone in Intermediate and High Risk Clinically Localized Prostate Cancer

Trial Profile

A Randomised Phase II Study of Neoadjuvant TAK-700 and Leuprorelin Acetate Followed by Surgery Versus Surgery Alone in Intermediate and High Risk Clinically Localized Prostate Cancer

Discontinued
Phase of Trial: Phase II

Latest Information Update: 12 Jul 2017

At a glance

  • Drugs Leuprorelin (Primary) ; Orteronel (Primary)
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Acronyms NEPTUNE
  • Most Recent Events

    • 02 Sep 2015 Accrual to date is 11% according to United Kingdom Clinical Research Network record.
    • 11 Jul 2015 Status changed from recruiting to discontinued as reported by European Clinical Trials Database record.
    • 27 Apr 2014 Accrual to date is 7% according to United Kingdom Clinical Research Network record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top